antibodi platform initi coverag assum coverag
emerg biotech stock
messag initi coverag biotechnolog compani ftsv assum coverag anoth
mru compani develop innov antibodi platform think repres attract invest
theme light increas clinic busi develop activ emerg clinic trial data overal revenu potenti
next-gener oncolog antibodi buy-rat stock ftsv mru rate neutral
next-gener bispecif antibodi platform repres major innov categori among emerg compani
focus oncolog previous highlight three innov area think favor posit within oncolog
therapeut categori link includ precis oncolog antibody-drug conjug cellular immunotherapi next-
gener bispecif antibodi platform view repres fourth theme high interest among small larg cap cancer
drug manufactur improv antibodi engin technolog recent year enabl develop modular antibodi
platform enhanc characterist includ improv pharmacokinet extend half-lif potent cell-kil t-
cell engag antibody-depend cellular cytotox target abil dual target inhibit well enhanc immun
regul local immune-activ thu open rang applic across oncolog treatment landscap believ
second gener bispecif antibodi product start reach level clinic valid potenti result valu inflect
next month
buy pt earli pipelin updat may repres potenti upsid investor await data
bemarituzumab well-posit gastric cancer asset posit phase data lack competitor access larg
asia gastric cancer market via partner zlab bemarituzumab antibodi late-stag clinic develop direct
gastric cancer high unmet need indic read promis phase monotherapi data
heavili pre-treat patient well safeti lead-in result commerci right greater china out-licens zlab
elig royalti net sale region investor await bemarituzumab phase data estim early-stag
in-hous asset earli clinic data readout esmo may
repres potenti near-term catalyst stock partner advanc cabiralizumab antibodi
may obtain potenti royalti world-wid net sale current valu exclus base bemarituzumab
opportun gastric cancer view rest pipelin sourc potenti upsid
ftsv buy pt scientif clinic leader target novel mechanist approach signific market
potenti success multipl earli clinical-phas data readout may establish proof-of-concept addit
tumor type ftsv view best-posit compani pursu new oncolog target given high pedigre leadership
team advisor well head-start potenti competitor ftsv current posit clinic proof-of-concept lead program
non-hodgkin lymphoma nhl compani demonstr monotherapi efficaci heavili pre-treat cancer
patient success think approach signific market opportun given tumor-agnost mechan numer early-
phase readout mid-to-l acut myeloid leukemia aml non-hodgkin lymphoma nhl colorect cancer
ovarian cancer ovca may continu valid approach drive addit upsid stock
page analyst certif import disclosur
mru buy pt differenti bispecif antibodi platform rapid target screen lead optim technolog
multipl clinic catalyst consider potenti upsid valuat singl program success
compani attract signific interest extern partner seek access bispecif antibodi gener
screen technolog result multipl develop licens deal in-hous mru develop multipl bispecif
target breast cancer aml colorect cancer think valu current stock
bispecif phase ii trial breast cancer given competit field modest phase efficaci view earli pipelin
agent includ egfr main valu driver
current valuat see consider potenti upsid one clinic program becom success compani
phase ii data readout across clinic asset repres potenti near-term catalyst
buy pt deep clinic pipelin bispecif t-cell engag dual checkpoint co-stimulatori antibodi
earli clinic data readout repres potenti upsid consider royalti potenti out-licens
asset product engin clinical- commercial-stag program develop in-hous out-licens
xmab bispecif technolog platform attract consider extern interest result oncolog bispecif develop licens
agreement alpmi rhhbi nv in-hous portfolio bispecif antibodi includ t-cell engag dual
checkpoint co-stimulatori molecul bind previously-valid target multipl early-phas clinic data readout
may serv potenti catalyst stock potenti resolut fda partial hold
could remov near-term overhang stock compani also cash runway ex-royalti believ potenti
royalti ultomiri mor potenti us approv could provid addit cashflow
neutral success phase breast cancer proof-of-concept acut myeloid leukemia aml posit
datapoint lower convict upsid opportun competit categori previous announc
margetuximab phase sophia trial third line metastat breast cancer met primari endpoint progression-fre
surviv said think competit categori intens itll take signific resourc time broaden
commerci opportun margetuximab view unlik tki antibodi margetuximab address
brain metastas describ kol largest unmet medic need metastat breast cancer impact half patient
patient without brain metastas antibody-drug conjug dsnki azn gener compel result breast
 gastric cancer may directli compet margetuximab similarli flotetuzumab enter crowd aml field multipl
competitor bispecif antibody-drug conjug develop compani sever catalyst line includ
full data disclosur pivot sophia trial multipl early-phas data updat late current valuat high
cost structur believ stock fairli valu
page analyst certif import disclosur
initiating/assum coverag
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
initi assum coverag emerg
biotechnolog stock focu innov antibodi pipelin
compani focus oncolog
previous highlight three innov area think favor posit within oncolog therapeut categori
link includ precis oncolog antibody-drug conjug cellular immunotherapi
next-gener bispecif antibodi platform view repres fourth theme high interest among small larg
cap cancer drug manufactur think could potenti build insight gain recent year key advanc
inhibitor car-t disappoint immun agonist made immuno-oncolog
improv antibodi engin technolog recent year enabl develop modular antibodi platform
enhanc characterist includ improv pharmacokinet extend half-lif potent cell-kil t-cell
engag antibody-depend cellular cytotox target abil dual target inhibit well enhanc
immun regul local immune-activ thu open rang applic across oncolog treatment
year pass sinc amgn mp blincyto first receiv fda-approv believ gener bispecif antibodi
product start reach level clinic valid potenti reach valu inflect next month
appli rate framework base fundament analysi upcom catalyst convict
consist broader coverag group stock select criteria includ revenu upsid potenti pipelin potenti
catalyst line-up balanc sheet flexibl valuat upsid downsid
consist assumpt loe gener biosimilar entri
consist wacc assumpt clinical-stag stock
termin growth rate termin year year post-ip expir
consist assumpt cog sg tax rate
page analyst certif import disclosur
initi assum coverag emerg
biotechnolog stock focu next-gener antibodi pipelin
posit view phase asset bemarituzumab gastric cancer posit poc data zlab partnership
earli pipelin sourc upsid initi phase data readout asset guid
cabiralizumab valuat given mix phase data difficulti pancreat cancer indic
leader target novel mechanist approach cancer therapi signific market potenti success
posit initi poc data key catalyst throughout mid-
expand pipelin ckit ind file guid
differenti mab platform rapidli screen gener optim preclin bispecif lead candid
local immune-activ
consider potenti upsid singl program success multipl clinic updat guid
broad mab pipelin major partnership agent clinic develop earli clinic updat
potenti lift partial clinic hold aml program remov near-term overhang
strong balanc sheet potenti license mor provid valuat floor
posit margetuximab phase data breast cancer lower convict commerci oppti competit categori
deep clinic stage pipelin high-cost oper structur less n/t upsid potenti current level base catalyst
line-up view
page analyst certif import disclosur
catalyst roadmap select
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
grow scientif industri interest novel oncolog antibodi
interest oncolog bispecif increas past decad greater scientif clinic studi
privat public compani across market cap size develop oncolog bispecif antibodi
larger manufactur in-licens bispecif antibodi commerci right technolog platform
high commerci potenti bispecif mab penetr market domin tradit mab
tradit antibodi hematolog malign immun checkpoint inhibit occupi half
current sale forecast consid select bispecif product clinic develop already-approv
blincyto account forecast bispecif antibodi sale indic signific
earli promis data establish proof concept high unmet need indic
posit poc data gener cell engag hematolog malign includ aml mm fl
initi poc data novel io concept dual checkpoint inhibitor local agonist could potenti valid
novel class product candid
page analyst certif import disclosur
emerg antibodi technolog allow research clinician
gener molecul highli versatil modular featur
antibodi drug
fc domain
antibodi
cytotox kill
page analyst certif import disclosur
bispecif antibodi highli modular may multipl
applic mechan action within oncolog
type
dual checkpoint co-
car-t-lik mechan action
demonstr efficaci
overcom resist immuno-
tumor achiev
stimul expans without
resist mediat activ
secondari pathway
page analyst certif import disclosur
scientif interest clinic trial bispecif antibodi steadili
grown last decad
earli research bispecif steadili grow
clinic trial studi initi
pubm bispecif antibodi articl year
bispecif antibodi clinic trial start year
blincyto indic b-
first bispecif antibodi t-
cell engag approv fda
page analyst certif import disclosur
novel antibodi product could potenti penetr market
success
consensu estim bispecif current includ amgn
blinatumomab total bispecif evaluatepharma consensu
select product mru
page analyst certif import disclosur
t-cell engag undergo extens clinic studi may
repres first wave bispecif antibodi product
oncolog bispecif t-cell develop
t-cell engag achiev via partner teneobio inc
page analyst certif import disclosur
t-cell engag undergo extens clinic studi may
repres first wave bispecif antibodi product
oncolog bispecif t-cell develop
t-cell engag achiev except engag
page analyst certif import disclosur
mechan dual-target target local agonist
repres new emerg class innov agent
oncolog bispecif develop
page analyst certif import disclosur
mechan dual-target target local agonist
repres new emerg class innov agent
oncolog bispecif develop
page analyst certif import disclosur
high strateg interest novel mab platform
select exampl oncolog bispecif partnership
develop
world-wide
right
greater china
page analyst certif import disclosur
high strateg interest novel mab platform
select exampl oncolog bispecif partnership
option
commerci right
right within
commerci
servier
one bispecif
right use mru
bispecif
page analyst certif import disclosur
high strateg interest novel mab platform
select exampl oncolog bispecif partnership
use gmxay
t-cell engag
research
develop
option licens
right bixab
page analyst certif import disclosur
proof-of-concept clinic dataset emerg multipl hematolog
select exampl recent bispecif antibodi data
page analyst certif import disclosur
multipl bispecif antibodi report posit data
serv earli clinic valid class
page analyst certif import disclosur
multipl bispecif antibodi report posit data
serv earli clinic valid class
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
rate buy platform focus
develop novel biolog advanc product late-
high unmet need gastric cancer fprx partnership
zlab allow compani access larg chines gastric cancer
market upon potenti approv current dont account
cabiralizumab valuat given recent withdraw
agent develop potenti posit newsflow repres
consider upsid current valuat earli stage
intrigu novel biolog repres longer-
term upsid pt current price slightli
street consensu
success probabl bemarituzumab gastric
viabil cabiralizumab given rhhbi remov anti-
mab clinic pipelin
market potenti antibodi given earli develop
therapeut potenti target
asco initi phase safeti data
esmo initi phase efficaci data
initi phase data
cabiralizumab phase result pancreat cancer
expect fully-enrol
bemarituzumab phase result gastric cancer
page analyst certif import disclosur
chart slide overal market perform
clinical-stag biotech compani develop antibodi direct emerg oncolog target cabiralizumab anti-
mab phase studi treatment pancreat cancer multipl phase studi evalu efficaci multipl
solid tumor bemarituzumab mab initi phase gastric cancer folfox cabiralizumab
fulli out-licens obtain ww royalti net sale bemarituzumab china right out-licens zai lab
clinical-stag pipelin product includ biolog direct novel emerg target undergo phase
studi express tumor direct fusion protein target recent
initi phase trial australia
page analyst certif import disclosur
need ind engin gener deep pipelin
consider royalti potenti bema given zlab
collabor larg chines gastric cancer popul
cabira stock pancreat cancer wide-open
market low bar success given lack approv
intrigu earli stage pipelin innov phase
biolog expect read data
clinic success rate pancreat cancer mix
small market opportun bema gastric cancer
rest pipelin still pre-poc
product engin late-stag clinic asset
out-licens product address high unmet need
clinical-stag product pipelin upsid
potenti yet reflect stock given disclosur
late stage data due earli stage asset
still pre-poc
consider revenu opportun bemarituzumab
fgfr gastric cancer success optimist
success probabl bema given support monotherapi poc
data heavili pre-treat patient partnership zlab
open signific opportun greater china region
view
cautiou cabiralizumab given rhhbi remov
mab pipelin data present
date note fprx poc data small popul
rhhbi remov mab pipelin sourc
upsid phase ii data posit
valuat upsid current ev believ
stock consider upsid given late-stag clinic asset
posit poc data potenti gener new ind pt
current share price peer
revenu estim street
page analyst certif import disclosur
posit bema given posit earli data lack competit
chines partnership may allow access larg mgc market
unmet need gastric cancer
gastric cancer ctdna
monotherapi activ heavili pre-treat gastric cancer
median prior line therapi
gene amplif associ poorer outcom
orr dcr gastric phase
year mo patient vs year mo
among confirm respons
post-ramucirumab post onartuzumab
patient hr p-valu
open field gastric cancer bema success
increment efficaci data ph fight safeti lead-in
fgfri small molecul bladder biliari cancer
azn gastric termin fail mpf
gastric cancer patient ctdna partial
respons patient stabl diseas last month
patient adjuv folfoxiri
event upcom data readout
zlab enrol chines patient phase fight trial
obtain commerci right greater china
elig royalti high teen low twenti
depend zlab enrol fight trial potenti
half total trial popul
develop regulatori commerci mileston
consider gastric cancer opportun china
annual metastat gastric cancer patient china vs
unit state
phase safeti lead-in present gi
initi data readout potenti
expect half patient trial come
greater china zlab collabor expect reduc
trial cost speed-up enrol earn call
page analyst certif import disclosur
cautiou cabira despit earli posit data potenti success upsid
valuat
fulli out-licens bristol myer squibb
earli data increment posit soc
elig tier royalti high teen low twenti
phase result w/ opdivo suggest potenti durabl
ww sale cabiralizumab
mileston cabira nivolumab combin
addit program cabiralizumab nivolumab
on-going phase ii inform pivot trial
ph signal-find trial without urelumab
ph i/ib melanoma nsclc rcc trial apexigen
ph ii pancreat radiotherapi biliari tract cancer
phase ii expect complet enrol ye
orr month mpf month mo
devt risk pancreat cancer high
poor success rate phase pancreat cancer trial
event upcom data readout
regimen test phase trial last year
complet phase ii enrol ye
incorpor clinic practic pancreat cancer
potenti data readout numer early-
commerci perform recent drug approv
manag commentari mention cabira
prior pancreat cancer expans
onivyd ipsey sale mack initi launch
sale
cours year go learn whether
inde signal combin nivo
cabiralizumab agent go know whether
combin chemotherapi base well abl
make judgment earn call
page analyst certif import disclosur
potenti posit news earli pipelin asset could
repres near-term upsid current valuat
could potent i-o asset
three immunotherapi mechan one molecul
co-stimul t-cell via without super-agon
moderate-to-high express observ multipl tumor
exhibit antibodi tegenero
includ breast ovarian endometri cancer
also express normal tissu spleen kidney
current phase dose-escal trial solid tumor
initi phase data plan
manag comment indic prefer tumor dont
respond well head neck liver etc phase ib
current phase dose-escal solid tumor basket
arm cancer initi data esmo
expans cohort breast ovarian endometri start
combin keytruda plan
still earli class upsid
fulli out-licens
event upcom data readout
antibodi first candid collabor
mileston plu tier mid-singl low double-
phase ia safeti data readout schedul
phase transit phase opdivo
potenti extern valid early-stag mab
respons orr pend
nv read ph i/ii
earli program
phase ia safeti data readout schedul
phase ib efficaci data readout schedul esmo
priorit tumor type expans cohort initi
advanc clinic develop phase ii
page analyst certif import disclosur
 regulatori commerci setback
potenti emerg new competitor
po bemarituzumab gastric cancer
posit data readout cabiralizumab ph ii
pancreat cancer initi pivot ph
dilut financ beyond assum
valu assign pipelin agent beyond
bemarituzumab gastric cancer
disappoint top-line result data updat
per dcf
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
incom statement sales- collabor royalties- total cogs- total cost oper incom interest incom interest expense- loss incom incom net incom dilut ep per share outstand bs cf debt- guggenheim secur llc estim sec file stock select rank
investor focu predominantli potenti early-stag asset
clinic data readout later-stag
cabiralizumab bemarituzumab
revenu forecast slightli consensu mean
forecast pos-adjust peak revenu bemarituzumab
royalti sale china
asco initi phase safeti data
esmo initi phase efficaci data
initi phase data
potenti data bemarituzumab fight cabiralizumab
pt current share price slightli peer
downsid bull/bear case month
compani current cashflow-neg runway
model posit cashflow begin
addit financ need achiev cash-flow break-even
guggenheim secur llc analysi rank scale low high
page analyst certif import disclosur
page analyst certif import disclosur
rate ftsv buy ftsv earli clinical-stag
compani focus develop antibodi
varieti advanc solid hematolog cancer
phase ii studi acut myeloid leukemia aml
non-hodgkin lymphoma nhl colorect cancer
ovarian cancer ovca schedul clinic data
readout result gener date still earli
may high revenu potenti given tumor-agnost approach
advanc develop stage vs competitor product
pt current share price slightli
street consensu
probability-of-success given earli develop
competit antibodi
overal market revenu potenti novel
mechan action
ind submiss anti-ckit
chart slide overal market perform
page analyst certif import disclosur
ftsv earli clinic stage compani focus develop novel therapeut oncolog lead product candid
antibodi undergo phase studi across multipl solid hematolog malign includ
colorect cancer ovarian cancer acut myeloid leukemia aml non-hodgkin lymphoma nhl multipl safeti efficaci data
readout expect anti-ckit antibodi indic hematopoiet stem cell bone marrow transplant
preclin studi ind expect anti-sirp antibodi preclin asset develop advanc
cancer lead candid select collabor agreement larger biopharma partner includ clinic develop cost-shar
mkkgi avelumab clinic trial suppli cetuximab atezolizumab rhhbi respect
page analyst certif import disclosur
bull innov excit compani
clinic poc novel immuno-oncolog approach
identifi pathway cancer cell
nobel prize physiolog medicin recipi
first-in-clin therapi advanc
develop potenti vs competitor
demonstr monotherapi efficaci
data heavili pre-treat patient ovarian
bear sirp approach yet
valid compani asset yet de-risk
promis clinic data still earli phase ii stage
termin program multipl competitor
celg stop aml surf halt ph expans
cohort due toxic
singl product stori clinic data readout fsi-
could becom crowd field multipl competitor
single-product stori consider market potenti
success view novel mechan
action target immune-infiltr macrophag wholli
depend tumor type clinic investig
ovarian cancer
ftsv asset first antibodi enter
clinic may succeed other fail
recent neg news around competitor asset
lack efficaci celg dose-limit toxic observ
lower-than-expect dose surf emerg howev
gener posit poc data includ earli efficaci
monotherapi
multipl early-phas trial event may serv
stock catalyst compani guid phase
ib ii readout aml nhl well phase ib ii
readout cetuximab ovarian cancer
avelumab ye
revenu forecast street consensu
averag pt current share
price slightli peer estim
downsid bull/bear case
page analyst certif import disclosur
antibodi earli highli promis asset
intrigu mechan action proof concept data
earli clinic proof concept efficaci data
antibodi monotherapi efficaci date
surf suspend phase trial given
patient prior platinum exposur respons on-going
month
hematolog dlt observ lower dose expect
celg termin program due disappoint
initi monotherapi data aml nhl still on-going
promis combin data rituximab nhl
cr rate r/r dlbcl durat yet reach
median month follow-up
cr rate r/r fl durat yet reach
monotherapi respons sirpa-fc fusion
present initi data oncolog
orr mg/kg dose sd
orr mg/kg sd
develop multipl tumor type
event upcom data readout
phase monotherapi ovarian cancer aml
azacytidin phase ib updat aml mid
phase combin regimen aml ovarian bladder cancer
rituximab phase updat nhl mid
phase ii combin regimen nhl
cetuximab phase updat
potenti long-term upsid program
avelumab phase ib updat ovarian
preclin program bone marrow transplant anti-ckit
antibodi solid tumor anti-sirpa antibodi
ckit antibodi may expand pool transplant-elig patient
celg nhl trial rituximab guid data
page analyst certif import disclosur
per dcf
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po indic posit initi
po ovarian cancer
po indic
peak market share within indic
clinic studi
valu
posit phase ii updat dlbcl fl
posit phase ib updat ovca aml
multipl neg data updat
trade cash valu
page analyst certif import disclosur
